Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
patient took the first dose of Vivotif and threw up "a little while later"; Case reference number US-BN-2025-001334 is a spontaneous case initially received from a pharmacist via Communications (reference number: USBAV25-1876) on 30-Jul-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, orally, for an unknown indication, and threw up "a little while later". On 31-Jul-2025 morning, the patient was scheduled to take the second dose of Vivotif. At the time of initial report, it was unknown if the patient recovered from the event 'vomiting'. The reporter did not provide seriousness and causality assessment for event 'vomiting'. No further information provided.; Reporter's Comments: A male patient of unspecified age took the first dose of Vivotif for an unknown indication and experienced a non-serious event of threw up a little while later. Vomiting is listed and expected for Vivotif per CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship, known vaccine safety profile and since the contributory role of the suspect vaccine cannot be excluded, the reported event has been considered as related to Vivotif. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age took the first dose of Vivotif for an unknown indication and experienced a non-serious event of threw up a little while later. Vomiting is listed and expected for Vivotif per CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship, known vaccine safety profile and since the contributory role of the suspect vaccine cannot be excluded, the reported event has been considered as related to Vivotif. This case is considered as non-serious.
Comments: None